- Home
- BTAI vs PDSB Comparison
BTAI vs PDSB Comparison
Compare BTAI & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- PDSB
- Stock Information
- Founded
- BTAI 2017
- PDSB 2005
- Country
- BTAI United States
- PDSB United States
- Employees
- BTAI N/A
- PDSB N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- PDSB Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- PDSB Health Care
- Exchange
- BTAI Nasdaq
- PDSB Nasdaq
- Market Cap
- BTAI 52.7M
- PDSB 48.0M
- IPO Year
- BTAI 2018
- PDSB N/A
- Fundamental
- Price
- BTAI $2.66
- PDSB $1.00
- Analyst Decision
- BTAI Buy
- PDSB Strong Buy
- Analyst Count
- BTAI 5
- PDSB 2
- Target Price
- BTAI $32.80
- PDSB $10.00
- AVG Volume (30 Days)
- BTAI 1.5M
- PDSB 535.9K
- Earning Date
- BTAI 11-13-2025
- PDSB 11-13-2025
- Dividend Yield
- BTAI N/A
- PDSB N/A
- EPS Growth
- BTAI N/A
- PDSB N/A
- EPS
- BTAI N/A
- PDSB N/A
- Revenue
- BTAI $868,000.00
- PDSB N/A
- Revenue This Year
- BTAI N/A
- PDSB N/A
- Revenue Next Year
- BTAI $614.78
- PDSB N/A
- P/E Ratio
- BTAI N/A
- PDSB N/A
- Revenue Growth
- BTAI N/A
- PDSB N/A
- 52 Week Low
- BTAI $1.17
- PDSB $0.85
- 52 Week High
- BTAI $13.28
- PDSB $3.75
- Technical
- Relative Strength Index (RSI)
- BTAI 38.51
- PDSB 31.57
- Support Level
- BTAI $2.42
- PDSB $0.94
- Resistance Level
- BTAI $2.70
- PDSB $1.05
- Average True Range (ATR)
- BTAI 0.19
- PDSB 0.05
- MACD
- BTAI 0.00
- PDSB -0.01
- Stochastic Oscillator
- BTAI 12.17
- PDSB 14.12
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.